Posted by Michael Wonder on 10 Dec 2022
FDA grants approval to atezolizumab for alveolar soft part sarcoma
9 December 2022 - Today, the FDA approved atezolizumab (Tecentriq, Genentech) for adult and paediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma.
Efficacy was evaluated in Study ML39345, an open-label, single-arm study in 49 adult and paediatric patients with unresectable or metastatic alveolar soft part sarcoma.
